ARM Innovation Hub
Advertisement: Lynch Wood Park
Advertisement: Bridge Fibre mid
Barr Ellison Solicitors – commercial property
RealVNC mid banner careers
RealVNC mid-banner general
Advertisement: Cambridge Network
Advertisement: Bradfield Centre mid
Advertisement: Mobas mid banner
Advertisement Cambridge China Centre
Advertisement: EY
1 November, 2017 - 13:35 By Tony Quested

Genestack joins global therapeutic powerhouse

Genestack Imad Yassin

Cambridge bio data management business Genestack has joined the Milner Therapeutics Institute – designed to create an ecosystem that fast tracks drug discovery and development.

The Institute is a new global therapeutic alliance which will bring the University of Cambridge, the Wellcome Trust Sanger Institute and the Babraham Institute together with over 66 affiliated partners such as pharmaceutical groups AstraZeneca, Astex and GSK.

Smart genomics data management is key to the success of the project and Genestack believes it has the technology to enhance the venture.

Vice-president Imad I. Yassin, said: “As sequencing technology shrinks to the size of a key ring and emerging technologies make it possible to track changes to the genome at single cell level, then all of a sudden genomics data becomes a streaming and wearable dataset.

“Real world evidence from patients is beginning to come into play. In an era of precision medicine these huge longitudinal clinical datasets will be a rich source of knowledge for drug development.

“Data production is cheap and processing power readily available; the big challenge is now to create tools to manage, search, aggregate and analyse these data sets.”

Yassin sees increasingly that data needs to be managed across organisational boundaries and between the academic and industry communities, an area where he says the company has particular strengths. He said Genestack had worked closely with leading pharma companies and academic communities to create an automated, robust, scalable bio-data platform and tools that allow discovery scientists to find relevant datasets and to collaborate.

“Our customers are Big Pharma and they are saying ‘you’ve sorted genomics data, what about proteomics emerging from academia? Clinical data? Imaging data? The microbiome? 

“The cost and complexity is opening the door for more cooperation and that is why the approach taken by the Milner Therapeutics Institute to create an ecosystem for pre-competitive drug discovery is so exciting.” 

Professor Tony Kouzarides is the founding director of the Milner Therapeutics Institute, which aims to increase collaborative research between academia and industry to convert ground breaking science into therapies and allow the fast track of innovation from bench to bedside.

Kouzarides explains that the Institute will be a “pipeline for drug discovery within an academic setting,” making it easier for academic researchers to work with pharmaceutical companies.

The Milner Institute has evolved from a research agreement signed in June 2015 between the University of Cambridge, the Wellcome Trust Sanger Institute and the Babraham Institute with three pharmaceutical companies: AstraZeneca, Astex and GSK. 

Since then the number of affiliates has increased to 66 and includes Pfizer, Shionogi, Elysium Health and Johnson and Johnson Innovation.

The academic community has access to cell lines and disease models that can be used to screen drugs for efficacy. This would enable drugs approved for use in certain diseases to be tested for use in other diseases – a practice called repositioning or repurposing.

“An academic might have developed a brain disease model using an organoid – a mini organ in a Petri dish,” explains Kouzarides. “We can use this to test drugs that have been licensed for use in other diseases such as arthritis or cancer.”

The approach can also be used for novel therapeutic agents to determine at an early stage if any in the pharmaceutical company’s portfolio are worth progressing along the drug development pipeline. This will reduce the cost of early drug discovery.

However, to use this knowledge effectively biologists in both research and academia need easy-to-use tools to track, manage, find, aggregate and analyse this data, so that the sum is greater than the parts. This is where Genestack comes in.

For example, cell lines can also be used for toxicity trials another major cost in drug development. Genomics provide a good proxy for measuring the impact of an active ingredient on the whole organism.

By exposing cells to a chemical you can measure gene expression and use this as a marker for dose response. With Genestack’s technology it is possible to run this type of analysis using a library of compounds with similar chemical structures.

Yassin says: “In drug development there are a vast number of biologists and chemists doing the research and they are customers for a very small number of bioinformaticians. Our aim is to build new tools and make them available so that discovery scientists don’t need the support of an expert for every problem.

“By participating within the Milner Therapeutics Institute we have access to a vibrant ecosystem of people all pushing the edge of what is possible. We are looking forward to working more closely with them to accelerate development of the tools they need.”

• PHOTOGRAPH SHOWS: Imad Yassin of Genestack

Newsletter Subscription

Stay informed of the latest news and features